24.12.20 (±Ý) 00:26

Dailypharm

X
"³ëº§»ó°ú L-¾Æ¸£±â´ÑÀÇ ÀÓ»óÀû °¡Ä¡"
µ¥Àϸ®ÆÊ 2017-11-29 12:14:54
"³ëº§»ó°ú L-¾Æ¸£±â´ÑÀÇ ÀÓ»óÀû °¡Ä¡"
µ¥Àϸ®ÆÊ 2017-11-29 12:14:54
ÀǾàÇ° ¼ººÐ ¸®ºä | ȲÀº°æ ¾à»ç(ºÎ»ê ¿À°Å¸®¾à±¹)



L-¾Æ½ºÆĸ£Æ®»ê-L-¾Æ¸£±â´Ñ°ú ³ëº§»óÀº ¾î¶² »ó°ü°ü°è°¡ ÀÖÀ»±î? ÃÖ±Ù ÀÌ °°Àº ¼ººÐÀ» ÇÔÀ¯ÇÑ ÀϹÝÀǾàÇ°, ¶ó¶ó¿Ã¶ó¶ó´Â Á¦Ç°ÀÌ ¾à±¹ Áø¿­´ë¿¡ ¿Ã¶ú´Ù.

1998³â ·Î¹öÆ® F ÆÛÄ¡°íÆ®¿Í ·çÀ̽º À̱׳ª·Î¿Í Æ丮µå ¹Â¶óµå°¡ ³ëº§ »ý¸®ÇлóÀ» °øµ¿ ¼ö»óÇß´Ù. ½ÉÇ÷°ü°è ½ÅÈ£Àü´Þ ºÐÀÚ·Î NO (nitric oxide, »êÈ­Áú¼Ò)¸¦ ¹ß°ßÇÑ °ø·Î¸¦ ÀÎ Á¤ ¹ÞÀº °ÍÀÌ´Ù. 20³â¼¼¿ù À̵éÀº Ç÷°ü±ÙÀ°¼¼Æ÷¸¦ À̿ϽÃÅ°´Â Ç÷°ü³»ÇǼ¼Æ÷¿¡¼­ »ý¼ºµÇ´Â Ç÷°üÀÌ¿Ï¿äÀÎ (Endothelium-derived relaxing factor, EDRF)À» ¹ß°ßÇß°í, ÀÌ EDRF°¡ ±âüÀÎ "NO"À̸ç ÀÎü¿¡¼­ È£¸£¸óÀÌ ¾Æ´Ñ ±âü°¡ ½ÅÈ£ Àü´Þ ¹°Áú·Î ÀÛ¿ëÇÏ´Â »õ ¿ø¸®¸¦ ¹àÇô³»¾ú´Ù.

¹Â¶óµå´Â ´ÏÆ®·Î±Û¸®¼¼¸°¿¡¼­ À¯¸®µÈ NO°¡ ¼¼Æ÷Áú ³» guanylate cyclase¸¦ È°¼ºÈ­½ÃÄÑ cGMP³óµµ¸¦ Áõ°¡½ÃÅ°°í ½ÉÀå Ç÷°ü ÆòÈ°±ÙÀ» À̿ϽÃÄÑ Çù½ÉÁõ¿¡ Àû¿ëÇÒ ¼ö ÀÖ´Ù´Â »ç½ÇÀ» , ÆÛÄ¡ÄÚÆ®´Â Ç÷°ü³»ÇǼ¼Æ÷ÀÇ ±â´ÉÀÌ »ì¾Æ ÀÖ´Â °æ¿ì ¾Æ¼¼Ä¥Äݸ° µî¿¡ ÀÇÇØ EDRF°¡ »ý¼ºµÇ¸é Ç÷°ü ÆòÈ°±ÙÀÌ À̿ϵȴٴ »ç½ÇÀ», À̱׳ª·Î´Â EDRF¸¦ ÀÛµ¿½ÃÅ°´Â ¹°ÁúÀÌ Ã¼³»¿¡¼­ »ý¼ºµÇ´Â NOÀÓÀ» ¹àÇû´Ù.

NO´Â ȦÀüÀÚÀÇ ÀÚÀ¯¶óµðÄ®À» °¡Áö°í ÀÖ¾î ¹ÝÀÀ¼ºÀÌ ÀÖÀ¸¸ç ¹°¿¡ ¾à°£ ³ìÀ¸¹Ç·Î Á¶Á÷À¸·Î ºü¸£°Ô È®»êµÇ¾î ¿©·¯ °¡Áö ´Ù¾çÇÑ ¿ªÇÒÀ» ¼öÇàÇÒ ¼ö ÀÖ´Ù.

 ¡ã [±×¸² 1] Ç÷°ü³»ÇǼ¼Æ÷¿¡¼­ÀÇ NO »ý¼º°ú Ç÷°ü ÆòÈ°±Ù ÀÌ¿Ï [A]
ÀÌÈÄ À̱׳ª·Î´Â NO °¡½º¸¦ ¸¶½Ã±âº¸´Ù ¾Æ¸£±â´Ñ °æ±¸ ¼·Ã븦 ÅëÇØ Ã¼³» NO»ý¼ºÀ» µ½´Â °ÍÀÌ °Ç°­À» À¯ÁöÇÏ´Â ±æÀ̶ó´Â ³»¿ëÀÇ °­¿¬À» Çѱ¹¿¡¼­µµ µÎ Â÷·Ê ÇÑ ÀûÀÌ ÀÖ´Ù.[B]

[±×¸² 2]¿¡¼­ º¸µíÀÌ NO´Â Çص¶À» À§ÇÑ °£ÀÇ urea cycle¿¡¼­µµ »ý¼ºÀÌ µÈ´Ù. ÀÌ urea cycleÀÌ ¿øÈ°È÷ µ¹¾Æ°¡±â À§Çؼ­´Â ¾Æ¸£±â´Ñ°ú ÇÔ²² ¾Æ½ºÆĸ£Æ®»êµµ ÇÊ¿äÇÏ´Ù. ÀÌ ¾Æ½ºÆĸ£Æ®»êÀº ¿¡³ÊÁö¸¦ »ý¼ºÇÏ´Â crebsȸ·ÎÀÇ Çʼö ¹°ÁúÀ̱⵵ Çѵ¥ urea cycleÀ» ÅëÇÑ ¾Ï¸ð´Ï¾ÆÀÇ Á¦°Å, ÇǷο¡ ´ëÇÑ ÀúÇ×¼º Áõ°¡, Áö±¸·Â Áõ°¡¸¦ À§ÇØ ¾²ÀδÙ. purineÀÇ Àü±¸Ã¼·Î¼­ ÇÙ»ê ÇÕ¼º¿¡ ¾²À̱⵵ ÇÑ´Ù.

 ¡ã [±×¸² 2] urea cycle and krebs cycle [C]

[±×¸² 1]ÀÇ eNOSó·³ NO¸¦ »ý¼ºÇϱâ À§Çؼ­´Â NOS¶ó´Â È¿¼Ò°¡ ÇÊ¿äÇѵ¥ 3°¡ÁöÀÇ ¼­ºêÇüÅ°¡ ÀÖ¾î °¢±â ´Ù¸¥ ¿ªÇÒÀ» ÇÑ´Ù. eNOS(endothelial NOS)¿Í nNOS(neuronal NOS), ºÐºñ °¡´ÉÇÑ ÇüÅÂÀÇ iNOS(¸é¿ª¹ÝÀÀ¿¡ ¿¬°ü, Ä®¸ðµÑ¸° °áÇÕÀ¸·Î ¸¹Àº ¾çÀÇ NO¸¦ »ý¼ºÇÏ¿© ¸é¿ª ´ã´ç)°¡ ÀÖ´Ù. ÀÌ eNOS, nNOS, iNOS´Â óÀ½¿¡ °¢°¢ Ç÷°ü³»ÇǼ¼Æ÷, ½Å°æ¼¼Æ÷, ´ë½Ä¼¼Æ÷¿¡¼­ ¹ß°ßµÇ¾úÁö¸¸ ½ÇÁ¦·Î´Â ´Ù¾çÇÑ ¼¼Æ÷³ª Á¶Á÷¿¡ ºÐÆ÷µÇ¾î ÀÖ´Ù.[D]

¸é¿ª°è(iNOS ÀÛ¿ë)¿¡¼­´Â Ç×¾Ï ¹× Ç׹̻ý¹° ÀÛ¿ë, ½Å°æ°è(nNOS ÀÛ¿ë)¿¡¼­´Â ½Å°æÀü´Þ¹°Áú, ¼øȯ±â°è(eNOS ÀÛ¿ë)¿¡¼­´Â Ç÷°üÈ®Àå¹°Áú·Î ÀÌÇØÇÏ¸é µÇ´Âµ¥ Ç÷°üÀúÇ×(Áï, Ç÷¾Ð)À» Á¶ÀýÇÏ°í, Àν¶¸°ºÐºñ, ±âµµÀúÇ×, ¿¬µ¿¿îµ¿, ±×¸®°í Ç÷°ü»ý¼º°ú ½Å°æ°èÀÇ ¹ß»ý, ±â¾ï µî¿¡ °ü¿©ÇÑ´Ù.

[NOÀÇ ¿ªÇÒ]

Á» ´õ Á¤È®È÷ ¾à±¹¿¡¼­ ¾Æ¸£±â´ÑÀ» Åõ¿©Çϱâ À§ÇØ ÇÊ¿äÇÑ ¿Ü±¹ ¹®Çå ¸î ÆíÀ» ¼Ò°³ÇÑ´Ù.

1. Ç÷°ü³»ÇǼ¼Æ÷ÀÇ ±â´ÉÀÌ Á¤»óÀÎ °æ¿ì [E] NO »ý¼ºÀÇ À¯ÀÏÇÑ ±âÁúÀÎ ¾Æ¸£±â´Ñ ¼·Ãë·Î Ç÷°ü ½ÉÀå°èÀÇ Ç×»ó¼ºÀÌ À¯ÁöµÇ¾ú°í µ¿¹°½ÇÇè¿¡¼­ Ç÷¼ÒÆÇ°ú Ç÷¾×ÀÀ°í ½Ã½ºÅÛ¿¡ ¿µÇâÀ» ÁÖ¾ú´Ù.


2. ¾Æ¸£±â´Ñ Åõ¿©´Â[F] °ú´ÙÇÑ È°¼º»ê¼Ò ¾ïÁ¦·Î I/R injury (±¹¼ÒºóÇ÷/Àç°ü·ù¼Õ»ó)¿¹¹æ È¿°ú°¡ ÀÖ´Ù.

3. ¿îµ¿¼±¼ö¿¡°Ô Áö¼ÓÀûÀ¸·Î L-arginine-L- aspartate¸¦ Åõ¿©Çϸé Áö¹æ»ê »êÈ­¸¦ ÃËÁøÇÏ°í Á¥»êÃàÀûÀ» ÁÙÀ̸ç ÃÑ»ê¼Ò ¼Òºñ¸¦ °¨¼Ò½ÃÅ°°í ¿îµ¿ È¿À²À» ³ôÀδÙ.[G]

4. ¿îµ¿Áß ¾Æ¸£±â´Ñ °ø±ÞÀº[H] ±ÙÀ°ÀÇ Æ÷µµ´ç ÀÌ¿ëÀ» Áõ°¡½ÃÅ°°í Áö¹æ»êÀÇ »êÈ­¸¦ ÃËÁø½ÃŲ´Ù.

5. Àå±â°£ÀÇ ¾Æ¸£±â´Ñ ¼·Ãë´Â[I] Á÷°æÀÌ ÀÛÀº °ü»óµ¿¸Æ ³»ÇǼ¼Æ÷ ±â´ÉÀ» Çâ»ó½ÃŲ´Ù.

6. °í¿ë·®ÀÇ ¾Æ¸£±â´Ñ °æ±¸Åõ¿©´Â[J] ¹ß±âºÎÀü¿¡ È¿°ú°¡ ÀÖ´Ù. 60³â´ëºÎÅÍ À¯·´¿¡¼­´Â ³²¼º ºÒÀÓ, ¹ß±âºÎÀü¿¡ ´ëÇÑ ¾Æ¸£±â´Ñ °ü·Ã ¿¬±¸°¡ Áö¼ÓµÇ¾î ¿Ô´Ù.

±¹³» ¹®Çåµµ »êÈ­Áú¼Ò¸¦ Å°¿öµå·Î È®ÀÎÇغ¸¸é Á¤¸» ´Ù¾çÇÑ ¿ëµµ·Î ÀÌ¿ëµÇ´Â °ÍÀ» ¾Ë ¼ö ÀÖ´Ù. ¾Æ¸£±â´Ñ ÇÑ °¡Áö º¹¿ëÀ¸·Î 3°¡ÁöÀÇ ¿ªÇÒÀ» ÇÒ ¼ö Àֱ⠶§¹®ÀÌ´Ù.

Ãâó¿Í °¢ÁÖ
[A] page 501"; name_="Myocardial Oxygen Supply and Demand Relationship: Zipes: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine"

[B] [»ç¶÷»ç¶÷] ³ëº§ ÀÇÇлó ¹ÞÀº ·çÀ̽º À̱׳ª·Î ±³¼ö Áß¾ÓÀϺ¸ 2004.11.21

[C} NMR metabolic profiling of serum identifies amino acid disturbances in chronic fatigue syndrome Christopher W. Armstrong ¿Ü5ÀÎ, Clinica Chimica Acta 413 (2012) 1525–.1531

[D] Synthesis of Nitric Oxide¿¡¼­ ¹ßÃé http://www.reading.ac.uk/nitricoxide/intro/no/synthesis.htm

[E] L-arginine and cardiovascular system

[F] L-Arginine Treatment Alters the Kinetics of Nitric Oxide and Superoxide Release and Reduces Ischemia/Reperfusion Injury in Skeletal Muscle

[G} THE PROLONGED INTAKE OF L-ARGININE-L-ASPARTATE REDUCES BLOOD LACTATE ACCUMULATION AND OXYGEN CONSUMPTION DURING SUBMAXIMAL EXERCISE

[H] L-Arginine infusion increases glucose clearance during prolonged exercise in humans

[I} Long-term L-Arginine Supplementation Improves Small-Vessel Coronary Endothelial Function in Humans

[K] Effect of oral administration of high-dose nitric oxide donor l-arginine in men with organic erectile dysfunction: results of a double-blind, randomized, placebo-controlled study
µ¥Àϸ®ÆÊ (dailypharm@dailypharm.com) ±âÀÚÀÇ ´Ù¸¥±â»ç º¸±â
  • Àμâ
  • Ä«Ä«¿ÀÅå
  • ÆäÀ̽ººÏ
  • Æ®À§ÅÍ
  • 0
/home/dailypharm/issueData2017/
¾à±¹ ÀÏ¹Ý¾à ¸ÅÃâ¾× Top 100(12¿ù)
¼øÀ§ »óÇ°¸í Ƚ¼ö
1 ŸÀÌ·¹³îÁ¤500mg(10Á¤) 26157
2 ÆÇÄÝ¿¡½º³»º¹¾× 14291
3 ±î½ºÈ°¸í¼öÅ¥¾× 11855
4 ÆÇÇǸ°Å¥¾× 10723
5 ¾ÖÅ©³íÅ©¸² 5761
6 ¾Æ·Î³ª¹Î°ñµåÇÁ¸®¹Ì¾ö(120Á¤) 1164
7 ÄÉÅäÅéÇöó½ºÅ¸(40¸Å) 3564
8 ¸®Áêºñ³Ø½ºÅ©¸² 801
9 ³ë½ºÄ«³ª°Ö 20g 2182
10 ÄÝ´ë¿ø ÄÚÇÁÅ¥½Ã·´ 8477
11 Ź¼¾ ¿¬Áúĸ½¶(10ĸ½¶) 10373
12 ŸÀÌ·¹³îÁ¤500mg(30Á¤) 3911
13 º¥Æ÷º§S¿¡½ºÁ¤ 648
14 ÀÕÄ¡ÆäÀ̽ºÆ®Ä¡¾à120g 2713
15 ºñÆÇÅÙ¿¬°í 30g 2959
16 ÅÙÅÙÃòÁ¤(120Á¤) 1331
17 ±¤µ¿¿øÅÁ 8203
18 º£³ªÄ¡¿À¿¡ÇÁ¾×75ml 7383
19 ÅÙÅÙÃòÁ¤(10Á¤) 10690
20 µÑÄÚ¶ô½º-¿¡½ºÀå¿ëÁ¤(40Á¤) 1919
21 ÀÌ°¡Åº¿¡ÇÁĸ½¶(60ĸ½¶*3) 1094
22 Å׶óÇÃ·ç ³ªÀÌƮŸÀÓ 3178
23 ¾Æ·º½º´ëÇü 3582
24 ¾ÖÅ©¸°°Ö 2245
25 ±¤µ¿¿ìȲû½É¿øÇöŹ¾×50ml(õ¿¬»çÇâ, º¯¹æ) 1131
26 ÈĽõò¿¬°í10g 3395
27 °Ôº¸¸°Á¤ 5004
28 ±¤µ¿°æ¿Á°í 267
29 ±¤µ¿¿ìȲû½É¿øȯ(»çÇâ, º¯¹æ) 307
30 ¾Æ·Î³ª¹Î°ñµå(100Á¤) 748
31 ±¤µ¿¿ìȲû½É¿øÇöŹ¾×50ml(¿µ¹¦Çâ, º¯¹æ) 1539
32 ÀÌÁö¿£6À̺ê(30ĸ½¶) 2959
33 µ¿¾ÆD-ÆÇÅ׳°í 2406
34 ÄÝ´ë¿øÄݵåÅ¥½Ã·´ 5299
35 ¸ðµåÄÝ¿¡½º 6048
36 Áö¸£ÅØÁ¤ 3855
37 Å׶óÇ÷ç Äݵå&ÄÚÇÁ ³ªÀÌÆ® 1873
38 ¸á¶óÅä´×Å©¸² 1077
39 ÄÝ´ë¿ø ³ëÁîÅ¥¿¡½º½Ã·´ 5212
40 ÀÕÄ¡ÆäÀ̽ºÆ®ÇÇÅæÄ¡µå150g 1408
41 ÄÉÆèÇöó½ºÅ¸ 3551
42 ¸¶µ¥Ä«¼ÖÄɾ°í10g 3053
43 ±¤µ¿½ÖÈ­ÅÁ 6117
44 ÈĽõò¿¬°í5g 3880
45 Àλ絹Ç÷¯½º(100Á¤) 641
46 ¿ÀÅ¥½Ã½ºÁ¡¾È¾×0.5ml*60°³ 1148
47 Ź¼¾ ¿¬Áúĸ½¶(30ĸ½¶) 2435
48 ºñ¸Æ½º¸ÞŸºñ 344
49 ¸Ó½Ã·ÐÁ¤ 1782
50 ¿ëÇ¥¿ìȲû½É¿ø¾×(¹«½ºÄÜ,º¯¹æ) 1564
51 ÄÚ¸ÞÅ°³ªÄ¸½¶ 3394
52 ¸¶±×ºñ¸Æ½º¿¬Áúĸ½¶ 388
53 ³ë½ºÄ«³ª°Ö10g 1508
54 ÄÚ¾ØÄ𠳪Àß½ºÇÁ·¹ÀÌ 1624
55 ŸÀÌ·¹³î8½Ã°£À̾˼­¹æÁ¤ 4483
56 ÇÁ·»Áî¾ÆÀ̵å·ÓÁ¡¾È¾×ÄðÇÏÀÌ ¾÷14ml 2869
57 ÄÉÅäÅéÇöó½ºÅ¸(34¸Å) 1278
58 Åõ¿¢½ººñÆ®¸®ÇÃÁ¤ 256
59 ¿ÀÆ®¸®ºó¸àÅç0.1%ºÐ¹«Á¦ 1397
60 ÇÁ·»Áî¾ÆÀ̵å·ÓÁ¡¾È¾×Äð ¾÷14ml 2851
61 ¹éÃʽ÷´Ç÷¯½º 2567
62 ÀÕÄ¡ ÇÁ·ÎÆú¸®½º 920
63 ´ë¿õ¿ì·ç»ç¿¬Áúĸ½¶(120ĸ½¶) 403
64 À¯ÇѺñŸ¹ÎCÁ¤1000mg 880
65 Ź¼¾·¹À̵ð 3476
66 ÄÝ´ë¿øÅ°Áî³ëÁî¿¡½º½Ã·´ 3551
67 ·Î°ÔÀÎÆû60g*3°³SET 187
68 Àλ絹(100Á¤) 537
69 ´ÏÄÚ·¹Æ®²­ 2mg (Äð¹ÎÆ®Çâ) 736
70 ¸¶µ¥Ä«¼Ö°Ö 1585
71 ºñ¸Æ½ºÁ¦Æ®Á¤ 177
72 ÀÌÁö¿£6À̺꿬Áúĸ½¶(10ĸ½¶) 4572
73 ¸¶µ¥Ä«¼ÖÄɾ°í 6g 2948
74 ¾Æ·º½ºÁßÇü 3139
75 ÇÁ·»Áî¾ÆÀ̵å·ÓÁ¡¾È¾×¼ø ¾÷14ml 2489
76 ¸ÞÀÌŲťÀå¿ëÁ¤(40Á¤) 1325
77 ŸÀÌ·¹³îÄݵ忡½ºÁ¤ 3158
78 Ä¡¼¾Ä¸½¶(60ĸ½¶) 535
79 ¿ëÇ¥¿ìȲû½É¿ø¾×50ml(õ¿¬»çÇâ,º¯¹æ) 889
80 Ä«¸®ÅäÆ÷ÅÙ¿¬Áúĸ½¶(60ĸ½¶) 336
81 ¾ÈƼǪ¶ó¹Î ´õºíÆÄ¿ö ´ëÇü 2052
82 ¸¶±×ºñ½ºÇǵå¾× 1473
83 Æǽõôĸ½¶(270ĸ½¶) 137
84 ¸¶±×ºñ½ºÇÇµå ´õºí¾×¼Ç 1006
85 ÄÝ´ë¿øÅ°ÁîÄÚÇÁ½Ã·´ 3202
86 Àλ絹Ç÷¯½º(270Á¤) 182
87 Ä¡¼¾Ä¸½¶(120ĸ½¶) 294
88 Á¶¾ÆÆË(10¸Å) 1767
89 ½ºÆ®·¾½ÇÆ®·ÎÅ°(Çã´Ï&·¹¸ó) 1985
90 ¸ñ¾Ø½ºÇÁ·¹ÀÌ 1300
91 °ÖÆ÷½º¿¤(6Æ÷) 1799
92 ¼¼ºñŸºñ°Ö 1012
93 ÀÌÁö¿£6ÇÁ·Î ¿¬Áúĸ½¶(30ĸ½¶) 1480
94 ÄÝ´ë¿øÅ°ÁîÄݵå½Ã·´(10ml*10Æ÷) 2381
95 ¾ÆÀ̹̻ê 277
96 °æ¹æ°¥±ÙÅÁ¾×75ml(Æ÷) 2584
97 ¸®¾ÈÁ¡¾È¾× 673
98 èÇÁ½Ã·´ 2176
99 ´ºº£ÀÎ¾× 512
100 ¼ÒÇÏÀÚÀÓÇ÷¯½ºÁ¤ 3554
Àüüº¸±â



ÀÎÅͳݽŹ®µî·Ï¹øÈ£: ¼­¿ï,¾Æ52715 | µî·ÏÀÏÀÚ 2019.11.20 | ¹ßÇàÀÏÀÚ 2019.11.20 | ¹ßÇàÀÎ : ÀÌÁ¤¼® | ÆíÁýÀÎ : °¡ÀÎÈ£
¹ßÇàÁÖ¼Ò: ¼­¿ï½Ã ¼ÛÆı¸ ¹ý¿ø·Î 128 ¹®Á¤ SK V1 GL ¸ÞÆ®·Î½ÃƼ Aµ¿ 401È£
ÀüÈ­ : 02-3473-0833 |Æѽº : 02-3474-0169 | û¼Ò³âº¸È£Á¤Ã¥(Ã¥ÀÓÀÚ °­½Å±¹)
Contact dailypharm@dailypharm.com for more information
µ¥Àϸ®ÆÊÀÇ ¸ðµç ÄÜÅÙÃ÷(±â»ç)¸¦ ¹«´Ü »ç¿ëÇÏ´Â °ÍÀº ÀúÀ۱ǹý¿¡ ÀúÃ˵Ǹç, ¹ýÀû Á¦À縦 ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù.